NVP — Competitive Intelligence Brief

NVP (NVP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease / Virology.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

NVP (NVP) — Johns Hopkins Bloomberg School of Public Health. NVP is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NVP TARGET	NVP	Johns Hopkins Bloomberg School of Public Health	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
Lamivudine Oral Solution	Lamivudine Oral Solution	ANRS, Emerging Infectious Diseases	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; Hepatitis B virus polymerase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
TRUVADA + Raltegravir	TRUVADA + Raltegravir	Fenway Community Health	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase and HIV integrase
JULUCA	JULUCA	ViiV Healthcare	marketed	Antiretroviral combination (integrase inhibitor + NNRTI)	HIV integrase and HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class